Report on the overall safety and tolerability of tolDC therapy

The overall goal of the ReSToRe project is to assess the safety and tolerability and demonstrate first proof-of-concept of administering clinical-grade vitamin D3-treated tolDC loaded with myelin-derived peptides via different administration routes to treat a well-defined subpopulation of MS patients. At this timepoint, assessment of safety and tolerability will be possible based on data gathered through standardized clinical, radiological and immunological evaluation of tolDC therapy in MS.